These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37324547)

  • 41. An updated review of epidemiological characteristics, immune escape, and therapeutic advances of SARS-CoV-2 Omicron XBB.1.5 and other mutants.
    Liu Z; Li J; Pei S; Lu Y; Li C; Zhu J; Chen R; Wang D; Sun J; Chen K
    Front Cell Infect Microbiol; 2023; 13():1297078. PubMed ID: 38156316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
    Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
    Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chasing SARS-CoV-2 XBB.1.16 Recombinant Lineage in India and the Clinical Profile of XBB.1.16 Cases in Maharashtra, India.
    Karyakarte RP; Das R; Rajmane MV; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Kulkarni PP; Nizarudeen S; Joshi S; Karmodiya K; Potdar V
    Cureus; 2023 Jun; 15(6):e39816. PubMed ID: 37397651
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
    Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
    Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern.
    Favorskaya IA; Shcheblyakov DV; Esmagambetov IB; Dolzhikova IV; Alekseeva IA; Korobkova AI; Voronina DV; Ryabova EI; Derkaev AA; Kovyrshina AV; Iliukhina AA; Botikov AG; Voronina OL; Egorova DA; Zubkova OV; Ryzhova NN; Aksenova EI; Kunda MS; Logunov DY; Naroditsky BS; Gintsburg AL
    Front Immunol; 2022; 13():822159. PubMed ID: 35281053
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity.
    Nakagama Y; Candray K; Kaku N; Komase Y; Rodriguez-Funes MV; Dominguez R; Tsuchida T; Kunishima H; Nagai E; Adachi E; Ngoyi DM; Yamasue M; Komiya K; Hiramatsu K; Uemura N; Sugiura Y; Yasugi M; Yamagishi Y; Mikamo H; Shiraishi S; Izumo T; Nakagama S; Watanabe C; Nitahara Y; Tshibangu-Kabamba E; Kakeya H; Kido Y
    J Infect Dis; 2023 Mar; 227(6):780-787. PubMed ID: 36546706
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
    Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
    Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice.
    Cai JP; Luo C; Wang K; Cao H; Chen LL; Zhang X; Han Y; Yin F; Zhang AJ; Chu H; Yuan S; Kok KH; To KK; Chen H; Chen Z; Jin DY; Yuen KY; Chan JF
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992395
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibodies induced by an ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1.
    Windsor IW; Tong P; Lavidor O; Moghaddam AS; McKay LGA; Gautam A; Chen Y; MacDonald EA; Yoo DK; Griffths A; Wesemann DR; Harrison SC
    Sci Immunol; 2022 Aug; 7(74):eabo3425. PubMed ID: 35536154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neutralization effect of plasma from vaccinated COVID-19 convalescents on SARS-CoV-2 Omicron variants.
    Xie Y; Liu L; Wang J; Zheng Y; Luo C; Ni W; He Z; Zhao X; Liu Y; He Y; Zheng S; Li L; Liu Z
    Front Immunol; 2022; 13():975533. PubMed ID: 36248883
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
    Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
    BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants.
    Sun H; Xu J; Zhang G; Han J; Hao M; Chen Z; Fang T; Chi X; Yu C
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746803
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants.
    Kuramochi T; Gan SW; Ho AWS; Wang B; Kageji N; Nambu T; Iida S; Okuda-Miura M; Chia WS; Yeo CY; Chen D; Lee WH; Ngoh EZX; Mohd Salleh SN; Wang CI; Igawa T; Shimada H
    MAbs; 2022; 14(1):2040350. PubMed ID: 35293276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reduced neutralization against Delta, Gamma, Mu, and Omicron BA.1 variants of SARS-CoV-2 from previous non-Omicron infection.
    Pidal P; Fernández J; Airola C; Araujo M; Menjiba AM; Martín HS; Bruneau N; Balanda M; Elgueta C; Fasce R; Valenzuela MT; Orellana A; Ramírez E
    Med Microbiol Immunol; 2023 Feb; 212(1):25-34. PubMed ID: 36370196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer.
    Ehmsen S; Pedersen RM; Bang LL; Asmussen A; Kragh A; Holm DK; Sydenham TV; Jensen TG; Jeppesen SS; Frederiksen H; Andersen TE; Ditzel HJ
    Cancer Cell; 2023 Apr; 41(4):649-650. PubMed ID: 36804967
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape.
    Witte L; Baharani V; Schmidt F; Wang Z; Cho A; Raspe R; Guzman-Cardozo MC; Muecksch F; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    bioRxiv; 2022 Aug; ():. PubMed ID: 36032981
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources.
    Sullivan DJ; Franchini M; Joyner MJ; Casadevall A; Focosi D
    Nat Commun; 2022 Oct; 13(1):6478. PubMed ID: 36309490
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test.
    Marot S; Bocar Fofana D; Flandre P; Malet I; Zafilaza K; Leducq V; Vivien D; Mrabet S; Poignon C; Calvez V; Morand-Joubert L; Marcelin AG; Gozlan J
    Life (Basel); 2022 Dec; 12(12):. PubMed ID: 36556429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.